Mazor Robotics Shareholders Approve Merger Agreement With Medtronic

CAESAREA, IsraelNov. 19, 2018 /PRNewswire/ — Mazor Robotics Ltd. (TASE: MZOR; NASDAQGM: MZOR), a pioneer and a leader in the field of robotic guidance systems, today announced that at a Special General Meeting of Shareholders held earlier today, Mazor Robotics shareholders approved the previously announced definitive merger agreement with wholly-owned subsidiaries of Medtronic plc (NYSE: MDT).

Approximately 53 percent of Mazor Robotics ordinary shares were represented in the meeting. Approximately 95 percent of the shares represented in the meeting which are neither held by a Medtronic affiliated party nor by a controlling shareholder of the Company or a shareholder with a personal interest in the merger proposal, were cast in favor of the merger.

Upon completion of the transaction, Mazor Robotics shareholders will receive $58.50 per American Depository Share, or $29.25 per ordinary share, in cash, for a total of approximately $1.64 billion. The transaction remains subject to certain closing conditions and is expected to close during Medtronic’s third fiscal quarter ending January 25, 2019.

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance System enables surgeons to conduct spine and brain procedures in an accurate and secure manner. For more information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the acquisition of Mazor, including the expected timing of the closing of the transaction, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on April 30, 2018 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

U.S. Contacts: EVC Group 
Michael Polyviou/Doug Sherk– Investors 
732-933-2754; 415-652-9100

SOURCE Mazor Robotics Ltd.

Patients with shoulder arthritis have new options to avoid risks of total shoulder replacement

ROSEMONT, Ill.Nov. 16, 2018 /PRNewswire/ — A new review article published in the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) finds arthroscopic (joint replacement or reconstruction) management could be a promising option for young, active patients diagnosed with GHOA.

Primary glenohumeral osteoarthritis (GHOA) is a common type of painful and debilitating shoulder osteoarthritis (OA). Shoulder OA leads to upper body dysfunction in over 20 million Americans. People with GHOA may have trouble throwing, swimming and lifting their arms to do everyday tasks. They often have pain centered in the back of their shoulder. As it progresses, shoulder arthritis pain may interrupt sleep. This condition can be especially frustrating for younger, active patients.

“Total shoulder replacement is not ideal for young, high-demand patients with GHOA,” explains Peter J. Millett, MD, lead author of the study and orthopaedic surgeon at the Steadman Clinic. “Instead patients under 50 years old or select active patients up to age 65 with advanced GHOA who haven’t experienced adequate relief from nonsurgical treatment may experience the greatest benefit from arthroscopic management.”

Over the last 15 years, Dr. Millett has been working on an arthroscopic approach to treat GHOA that preserves the shoulder joint, decreases pain and improves function. This approach, the Comprehensive Arthroscopic Management (CAM) procedure, is also now being successfully utilized by other orthopaedic shoulder specialists for some patients to treat shoulder osteoarthritis.

Outcomes for patients with advanced symptomatic GHOA who underwent CAM procedures include:

  • Significantly improved ability to complete daily activities and reduced pain and instability as reported by both patients and doctors (known as the American Shoulder and Elbow Surgeons Shoulder Score (ASES));
  • Significant rates of preventing total shoulder arthroplasty (TSA) at one, two, three and five years following CAM procedures; and,
  • Median patient satisfaction rate of nine out of 10 five years after CAM procedures among patients who did not need TSA.

Osteoarthritis is the most frequent cause of disability in the United States. Cartilage breaks down, and the body’s healing process can ruin the smooth joint surfaces needed for typical movement. Related inflammation also limits motion. Doctors have multiple surgical and non-surgical treatment options for osteoarthritis. Physical therapy, home exercise, cortisone injections, and anti-inflammatory medications such as ibuprofen may offer relief for osteoarthritis, but the scientific literature supporting these approaches is limited. Despite this, Dr. Millet notes that most doctors will try one or more of these methods before suggesting surgery.

If nonsurgical efforts fail, removing damaged cartilage or bone (debridement) or arthroplasty are potential next steps. However, each of these approaches have potential downsides, including long recovery times, surgical risks and acceleration of the arthritis with more pain, stiffness and dysfunction. With arthroplasty, additional risks related to the artificial joint may include pain, dysfunction and wearing out of implants over time.

In search of a solution to address these shortcomings, orthopaedic surgeons have identified new combinations of treatments that preserve joints and delay or avoid arthroplasty. Dr. Millet and his colleagues combined new and existing procedures to treat this specific arthritis.

“The CAM procedure is a minimally invasive surgery that removes mechanical irritants from the joint, reshapes the humerus to make it round again and also to decrease any impingement on the adjacent nerves,” says Dr. Millett. “The overall goal is to achieve a synergistic benefit with pain relief and functional restoration, without burning bridges for future surgeries, all while delaying joint replacement or perhaps even avoiding it altogether.”

Advantages of arthroscopic management as compared to total shoulder arthroplasty include delaying or avoiding arthroplasty, preserving the joint, and preserving future treatment options. Disadvantages of CAM include that the procedures are technically demanding, long-term outcomes remain unknown, and that there is no guarantee a patient will not need arthroplasty in the future.

“The human and economic costs of shoulder arthritis are substantial and conventional treatment has significant shortcomings. This new, more tailored approach is potentially good news for GHOA sufferers. “Long-term data of patients who have undergone the CAM procedure show promising, but not perfect, results,” Dr. Millett concludes.

The full study is available at:
More information about arthritis of the shoulder is at OrthoInfo

More information about the AAOS
 and JAAOS
Follow the AAOS on FacebookTwitter and Instagram

Follow the conversation about JAAOS on Twitter

From the Steadman Philippon Research Institute (Dr. Millett and Dr. Fritz), and the Steadman Clinic, Steadman Philippon Research Institute (Dr. Frangiamore and Dr. Mannava), Vail, CO. Dr. Millett or an immediate family member has received royalties from Arthrex and MedBridge; serves as a paid consultant to Arthrex; has stock or stock options held in Game Ready and VuMedi; and has received research or institutional support from Arthrex, Össur, Siemens, and Smith & Nephew. Dr. Fritz or an immediate family member has received research or institutional support from Arthrex, Össur, Smith & Nephew, and Vail Valley Medical Center. Dr. Mannava or an immediate family member serves as a board member, owner, officer, or committee member of the Arthroscopy Association of North America. Neither Dr. Frangiamore nor any immediate family member has received anything of value from or has stock or stock options held in a commercial company or institution related directly or indirectly to the subject of this article. JAAOS – Journal of the American Academy of Orthopaedic Surgeons: November 1, 2018 – Volume 26 – Issue 21 – p 745–752
doi: 10.5435/JAAOS-D-17-00214

SOURCE American Academy of Orthopaedic Surgeons

Related Links

Michel Orsinger Assumes Role as Chairman of LimaCorporate’s Advisory Board

SAN DANIELE DEL FRIULI, ItalyNovember 19, 2018 /PRNewswire/ —

LimaCorporate is pleased to announce that Michel Orsinger, Board Member of LimaCorporate’s Advisory Board, will assume the role of Chairman of the Board. Michel joined the Advisory Board mid-2017 following a long and successful global career in Orthopaedics.

Michel Orsinger held the position of Worldwide Chairman DePuy Synthes Companies at Johnson & Johnson (“J&J”) from 2012 to 2015, where he was also a member of J&J’s Global Management Team.  Michel joined J&J following the sale of Synthes Inc. for $20 billion in 2012.  Subsequently, Michel established the worldwide largest and most comprehensive orthopaedic company. Prior to his leadership role at J&J, Michel Orsinger was COO and CEO of Synthes Inc. for eight years and spent 11 years with Novartis.

Today, Michel is an investor as well as board member of several start-up companies, Chairman of a VC Fund and a senior advisor to EQT. He also joined the Board of the pharmaceutical company Takeda in 2016.

Valentin Chapero, who held the Chairman of the Board position from 2016, contributed to focusing the LimaCorporate strategic value proposition in terms of market approach, product portfolio and core technologies. He promoted operational excellence through the alignment of business processes as well as providing direction to expand LimaCorporate in M&A activities. Valentin also influenced the important country reorganizations rendering a customer-focused organization in many of LimaCorporate’s direct markets. Michel will now build on Valentin’s work making use of his global leadership experience, Orthopaedic expertise and extensive industry network.

Michel Orsinger will bring LimaCorporate to the next level as he has demonstrated in many other companies. He is a quality veteran of our industry with a strong track record of success which will enable him and the Advisory Board to support LimaCorporate’s development, including to push our digital agenda recently accelerated with the milestone-based acquisition of TechMah Medical LLC. I look forward to closely collaborating with Michel and I would like to personally thank Valentin for his dedication and leadership he brought to LimaCorporate”, said Luigi Ferrari, CEO of Lima Corporate.

About LimaCorporate 
LimaCorporate is a global medical device company providing reconstructive and custom-made Orthopaedic solutions to surgeons who face the challenges of improving the quality of life of their patients. Based in Italy, LimaCorporate is committed to the development of innovative products and procedures to enable surgeons to select ideal solution for every individual patient. LimaCorporate’s product range includes large joint revision and primary implants and complete extremities solutions including fixation.

For additional information on the Company, please visit:

SOURCE Limacorporate S.p.A.

(Logo: )

BONESUPPORT™ – Positive Results From The CERTiFy Study Comparing Cerament®|Bone Void Filler With Autograft

Lund, Sweden, 08.00 CET, 19 November 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, today announces positive top-line data from the CERTiFy (CERAMENT® Treatment of Tibia Plateau Fracture defects) study comparing CERAMENT|BVF with autologous iliac bone graft (autograft).BONESUPPORT CEO Emil Billback said:” Successfully completing the ground-breaking CERTiFy study, to demonstrate CERAMENT BVF is non-inferior to autograft in treating tibia plateau fracture defects, is a major milestone for BONESUPPORT. We expect the results from the study to catalyse a change in the standard of care for this kind of injury given that our synthetic bone graft is now proven to be as good as autograft, which requires a second surgical procedure to harvest bone from the patient’s hip. These data, which clearly differentiate CERAMENT BVF, will play a key role in our commercial strategy to increase our share of the synthetic bone graft substitute market in both Europe and the U.S..”

CERTiFy, a prospective, multi-center, controlled, randomized trial, enrolled 137 patients with fresh traumatic depression fracture of the proximal tibia across 20 participating centers in Germany. Patients were randomized to receive either CERAMENT BVF or autograft. Professor Pol. M. Rommens, Head of Department of Orthopaedics and Traumatology at The University Medical Centre Mainz was the study’s Principle Investigator.

The CERTiFy study met its primary endpoint with CERAMENT BVF being non-inferior to autograft in terms of Physical Component Summary (SF-12 v2) at week 26. A publication providing more complete data from the CERTiFy study is expected in Q1 2019.

Professor P.M. Rommens said: “We are pleased to report positive top-line results from the CERTiFy study. Bone graft substitutes are widely used for augmentation of post-traumatic bone defects. However, no direct randomized clinical comparison to autologous bone grafting, the so-called “gold-standard” in reconstruction of bone defects, has been previously conducted. CERTiFy clearly demonstrates that CERAMENT BVF is non-inferior to autograft across several key clinical parameters. These findings pave the way for a potential change in the standard of care for post-traumatic bone defects given the ease of use and other benefits that CERAMENT BVF delivers. I look forward to providing more data from this ground-breaking study in a publication which is planned for Q1 2019”


Emil Billbäck, CEO

+46 (0) 46 286 53 70

Håkan Johansson, CFO

+46(0) 46 286 53 70

Citigate Dewe Rogerson

Pip Batty, David Dible, Shabnam Bashir

+44 (0)20 7638 9571


CERAMENT|BONE VOID FILLER is used to fill gaps and voids in bone, for example those caused by trauma and benign bone tumors. It is the only injectable and moldable synthetic bone substitute that remodels to host bone within 6-12 months, and is radiopaque, making it ideal for minimally invasive surgery and open procedures. CERAMENT can be used to augment hardware during surgery, and the unique material combination resists crack formation and propagation when drilled.


BONESUPPORT is an innovative commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs directly into the bone void.

BONESUPPORT’s bio-ceramic bone graft substitutes CERAMENT®|BONE VOID FILLER (BVF), CERAMENT®|G* and CERAMENT® V* are all based on the Company’s novel and proprietary technology platform.

The Company’s products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis), ortho-oncology and foot and ankle.

BONESUPPORT’s total sales increased from SEK 62 million in 2015 to SEK 129 million in 2017, representing a compound annual growth rate of 45%.

BONESUPPORT is currently conducting two important clinical trials to generate data demonstrating the clinical and health economic benefits its products deliver. The first trial, CERTiFy, is comparing CERAMENT BVF with autograft, the most widely used approach for managing bone voids. Top line results from this successful study showed that CERAMENT BVF met its primary endpoint of being   non-inferior to autograft. A publication providing more complete data from the CERTiFy study is expected in Q1 2019.

The FORTIFY study is assessing CERAMENT G’s ability to improve on the standard-of-care management of patients with open fractures of the tibial diaphysis. The primary endpoints of the trial will include the absence of deep infection at the fracture site and a reduction in the number of secondary procedures intended to promote fracture union. Data from this study will be used for a planned Premarket approval filing with FDA in 2020.

The Company’s research and development is focused on extending the use of its CERAMENT technology into further indications via the incorporation of additional drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote bone growth.

BONESUPPORT is also preparing to expand its product offering in the US and has entered into strategic agreements with Collagen Matrix Inc. and MTF Biologics to gain access to products that are complementary to CERAMENT BVF.

BONESUPPORT is listed on Nasdaq Stockholm and trades under the ticker “BONEX” (ISIN code: SE0009858152). Further information is available at

*CERAMENT G: Not available in the United States, for investigational use only.
CERAMENT V: Not available in the United States.

BONESUPPORT® and CERAMENT® are registered trademarks

This information is such information as BONESUPPORT HOLDING AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00am CET on 19 November 2018.

 About Us

BONESUPPORT is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs directly into the bone void.BONESUPPORT’s bio-ceramic bone graft substitutes CERAMENT® BONE VOID FILLER (BVF), CERAMENT® G* and CERAMENT® V* are all based on the Company’s novel and proprietary technology platform.The Company’s products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis) and infected diabetic foot.BONESUPPORT’s total sales increased from SEK 62 million in 2015 to SEK 129 million in 2017, representing a compound annual growth rate of 45%.The Company’s research and development is focused on the continuing development and refinement of its CERAMENT technology to extend its use into additional indications by the elution of drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote bone growth.In addition, BONESUPPORT is looking at opportunities to expand its product offering in the US and has entered into a strategic agreement with Collagen Matrix Inc. to market and distribute products that are complementary to CERAMENT BVF.BONESUPPORT is listed on Nasdaq Stockholm and trades under the ticker “BONEX” (ISIN code: SE0009858152). Further information is available at*CERAMENT G: Not available in the United States, for investigational use only.CERAMENT V: Not available in the United States.BONESUPPORT™ and CERAMENT® are registered trademarks.

Colfax to Acquire DJO Global for $3.15 Billion in Cash

ANNAPOLIS JUNCTION, MD, Nov. 19, 2018 (GLOBE NEWSWIRE) — Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced it has entered into a definitive agreement to acquire DJO Global Inc. (“DJO”) from private equity funds managed by Blackstone for $3.15 billion in cash. DJO is a global leader in orthopedic solutions, providing orthopedic devices, software and services spanning the full continuum of patient care, from injury prevention to rehabilitation.

“The acquisition of DJO is a compelling next step in the strategic evolution of Colfax that creates a new growth platform in the high-margin orthopedic solutions market,” said Matt Trerotola, President and Chief Executive Officer of Colfax. “As a clear market leader in bracing and rehabilitation systems – with a track record of innovative new products, globally recognized brands, and a diverse product portfolio – DJO is well-positioned to benefit from secular trends driven by changing demographics and increased preventive healthcare. This transaction reflects our strategic intent to diversify our portfolio and end-market exposure, reduce cyclicality, and increase profitability. We see significant opportunities to apply our proven Colfax Business System across DJO to create a continuous improvement culture, further improve productivity and margins, and accelerate innovation and new product development.”

Mr. Trerotola continued, “We are committed to reducing leverage and restoring balance sheet flexibility near-term and will explore strategic options for our Air and Gas Handling business. Longer term, we see tremendous opportunities to build our new medical technology platform with additional investment. We are excited to welcome DJO’s strong management team and talented associates to the Colfax family.”

“Joining Colfax is a win for our customers, and all DJO stakeholders,” said Brady Shirley, DJO President and CEO. “Colfax has the financial strength, experience, and proven business system to support our operational performance and growth.  Importantly, they are committed to our mission to get and keep people moving, and we are confident that the Colfax team’s operating expertise across a broad array of businesses makes them the ideal partner to help us build on our momentum, drive new levels of innovation, and continue to deliver outstanding service to our customers.”

Upon closing of the transaction, DJO Global will operate as a new segment within Colfax and be led by Mr. Shirley, who will report directly to Mr. Trerotola.

With leadership positions in most product categories, DJO provides a broad range of orthopedic care solutions including bracing, reconstructive implants, rehabilitation devices, software and services. Known for its innovative products, DJO’s portfolio of iconic brands are trusted by patients, athletes, and healthcare professionals globally. Headquartered in Vista, California, DJO has approximately 5,000 employees across 18 locations around the world. DJO’s revenue was $1.2 billion and adjusted EBITDA was $269 million for the twelve-month period ending September 2018.

Financing & Transaction Details
The transaction, which is expected to close in the first quarter of 2019, is expected to deliver adjusted EPS accretion in the first full year after closing. In addition, Colfax expects to realize future tax benefits from DJO’s approximately $800 million of net operating loss carryforwards.

Colfax expects to finance the transaction with approximately $100 million of cash from its balance sheet, proceeds from credit facilities and a contemplated debt offering, and $500 to $700 million from a contemplated offering of equity or equity-linked securities. J.P. Morgan and Credit Suisse have committed to provide bridge financing for the transaction. Colfax expects to maintain its existing debt ratings and will prioritize deleveraging to reduce its net leverage ratio to the mid-3x range by the end of calendar 2019. In connection with its deleveraging plans, Colfax is evaluating strategic options for its Air and Gas Handling business. Colfax does not intend to undertake any material acquisitions or share repurchases until its leverage metrics return to targeted levels.

The acquisition is subject to customary closing conditions, including receipt of applicable regulatory approvals.

J.P Morgan is serving as financial advisor and Kirkland & Ellis is serving as legal advisor to Colfax.  Goldman, Sachs & Co. LLC, Credit Suisse, and Wells Fargo Securities, LLC are serving as financial advisors and Simpson Thacher & Bartlett LLP is serving as legal advisor to DJO.

Conference Call and Webcast
Colfax will host a conference call to discuss the transaction today at 8:30 a.m. Eastern. The call will be open to the public through 877-303-7908 (U.S. callers) or +1-678-373-0875 (international callers) and referencing the conference ID number 6068397 or through webcast via Colfax’s website at under the “Investors” section. Access to a supplemental slide presentation can also be found at the Colfax website under the same heading. Both the audio of this call and the slide presentation will be archived on the website later today and will be available until the next quarterly call.

About Colfax Corporation
Colfax Corporation is a leading diversified technology company that provides air & gas handling and fabrication technology products and services to customers around the world principally under the Howden and ESAB brands. Colfax believes that its brands are among the most highly recognized in each of the markets that it serves. The Company uses its Colfax Business System (CBS), a comprehensive set of tools, processes and values, to create superior value for customers, shareholders and associates. Colfax is traded on the NYSE under the ticker “CFX.” Additional information about Colfax is available at

About DJO Global
DJO Global is a leading global provider of medical technologies designed to get and keep people moving. The Company’s products address the continuum of patient care from injury prevention to rehabilitation, enabling people to regain or maintain their natural motion. Its products are used by orthopedic surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers and other healthcare professionals. In addition, many of the Company’s medical devices and related accessories are used by athletes and patients for injury prevention and at-home physical therapy treatment. The Company’s product lines include rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management and physical therapy products. The Company’s surgical division offers a comprehensive suite of reconstructive joint products for the hip, knee and shoulder. DJO Global’s products are marketed under a portfolio of brands including Aircast®, Chattanooga, CMF™, Compex®, DonJoy®, ProCare®, DJO® Surgical, Dr. Comfort® and Exos™.
Additional information about DJO Global is available at

This press release contains forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Colfax’s plans, objectives, expectations and intentions and other statements that are not historical or current fact. Forward-looking statements are based on Colfax’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Colfax’s results to differ materially from current expectations include, but are not limited to risks and uncertainties regarding Colfax and DJO’s respective businesses and the proposed acquisition, and actual results may differ materially. These risks and uncertainties include, but are not limited to, (i) the ability of the parties to successfully complete the proposed acquisition on anticipated terms and timing, including obtaining required regulatory approvals and other conditions to the completion of the acquisition, (ii)  access to available financing on a timely basis and reasonable terms, (iii) the effects of the transaction on Colfax and DJO operations, including on the combined company’s future financial condition and performance, operating results, strategy and plans, including anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, losses, future prospects, business and management strategies for the management, expansion and growth of the new combined company’s operations, and (iv) other factors detailed in Colfax’s and DJO’s respective reports filed with the U.S. Securities and Exchange Commission on Form 10-K and Form 10-Q.  In addition, these statements are based on a number of assumptions that are subject to change. This press release speaks only as of the date hereof. Colfax disclaims any duty to update the information herein.

The term “Colfax” in reference to the activities described in this press release may mean one or more of Colfax’s global operating subsidiaries and/or their internal business divisions and does not necessarily indicate activities engaged in by Colfax Corporation.

Non-GAAP Financial Measures and Other Adjustments  
Colfax has provided in this press release financial measures for DJO Global that have not been prepared in accordance with GAAP, including Adjusted EBITDA and Leverageable Adjusted EBITDA.  DJO Global provided Colfax with this information, which was derived from DJO Global’s historical unaudited financial statements for the twelve months ended September 29, 2018 and has not been audited or reviewed by Colfax’s or DJO Global’s independent public accountants.  DJO Global defines Adjusted EBITDA as net income (loss) attributable to DJO Global plus interest expense, net, income tax provision (benefit), and depreciation and amortization, further adjusted for certain non-cash items, non-recurring items and other adjustment items as permitted in calculating covenant compliance and other ratios under the agreements governing the outstanding debt of DJO Global’s subsidiary DJO Finance, LLC (DJO Finance).  DJO Global defines Leverageable Adjusted EBITDA as Adjusted EBITDA, as further adjusted to reflect certain additional non-cash items, non-recurring items and other adjustment items permitted in calculating covenant compliance and other ratios under the agreements governing the outstanding debt of DJO Finance. Adjusted EBITDA and Leverageable Adjusted EBITDA should not be considered as an alternative to net income (loss) attributable to DJO Global or other performance measures presented in accordance with GAAP, or as an alternative to cash flow from operations as a measure of liquidity.

Colfax believes this presentation of DJO Global’s Adjusted EBITDA and Leverageable Adjusted EBITDA is useful and helps management, investors and rating agencies enhance their understanding of the impact of the DJO Global acquisition on Colfax’s financial performance.  However, Adjusted EBITDA and Leverageable Adjusted EBITDA do not have a standardized meaning, and different companies may use different Adjusted EBITDA definitions.  Therefore, DJO Global’s definition of Adjusted EBITDA and Leverageable Adjusted EBITDA may not be comparable to the definitions used by other companies.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of Adjusted EBITDA and Leverageable Adjusted EBITDA to the most directly comparable GAAP financial measure. A reconciliation of Adjusted EBITDA and Leverageable Adjusted EBITDA to GAAP net income has been provided below.

DJO Global, Inc.
Adjusted EBITDA Reconciliation of GAAP
Dollars in thousands

Ended September 29, 2018
Adjusted EBITDA
Net income attributable to DJO Global $ 397
Discontinued operations (567 )
Interest expense, net 181,091
Income tax provision (benefit) (55,196 )
Depreciation and amortization 107,646
Loss on disposal of assets, net 295
Restructuring and reorganization (1) 41,121
Acquisition integration 2,096
Blackstone monitoring fee 975
Financial reporting alignment (9,071 )
Adjusted EBITDA $ 268,787
Future cost savings 20,533
Stock compensation expense 4,522
Leverageable Adjusted EBITDA $ 293,842

(1) Consists of costs related to the company’s business transformation projects to improve the company’s operational profitability and liquidity.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended or via an exemption from the requirements of the Securities Act.

Kevin Johnson, Vice President                                   
Colfax Corporation                                                      

Jim Barron or Jenny Gore
Sard Verbinnen & Co.

RTI Surgical® Announces HealthPartners’® Positive Coverage Decision for Minimally Invasive Sacroiliac Joint Fusion Surgery

November 19, 2018

ALACHUA, Fla.–(BUSINESS WIRE)–RTI Surgical, Inc. (Nasdaq: RTIX), a global surgical implant company, announced HealthPartners, the largest consumer governed nonprofit health care organization in the United States, issued a positive coverage decision for minimally invasive sacroiliac (SI) joint fusion surgery, effective November 1, 2018. This decision expands access to RTI’s SImmetry System for HealthPartners members considering treatment for SI joint pain or dysfunction. The SImmetry System is a minimally invasive surgical solution that uses proprietary decortication technology, bone graft and threaded fixation to facilitate bone fusion, providing an opportunity for long-term pain relief.

It has been reported that up to 30 percent of all chronic low back pain, the second most common cause of disability in American adults, is due to SI joint dysfunction. SI joint fusion surgery using the SImmetry System is designed to stabilize the dysfunctional SI joint by fusing the sacrum and the pelvic bone together.

“As a surgeon in the HealthPartners network who has experience using the SImmetry System, this positive coverage decision is a win for patients suffering from SI joint dysfunction,” said Edward Santos, M.D., a spine surgeon specializing in neck, back, cervical, thoracic and lumbar spinal disorders, and minimally invasive surgery at Summit Orthopedics in Minneapolis. “The SImmetry System is a minimally invasive surgical solution that promotes SI joint fusion through decortication, with a growing body of clinical evidence showing improvements in pain, disability and opioid use for SI joint patients.”

“RTI is encouraged by HealthPartners’ decision, which expands access to the SImmetry System for patients with SI joint pain or dysfunction,” said Camille Farhat, President and CEO, RTI Surgical. “The SImmetry System is supported by a growing body of evidence suggesting long-term pain relief for these patients. We are committed to advancing clinical data for the SImmetry System to aid in further payor decisions.”

Clinical Data Supporting the SImmetry System

The ongoing EVoluSIon Clinical Study is evaluating the impact of SImmetry on SI joint fusion and pain reduction in 250 patients across 23 sites. An early analysis of the first 50 patients published in December 2017 showed a 54 percent reduction in SI joint pain at six months, as well as a 55 percent reduction in opioid use.A separate CT fusion study on the SImmetry System demonstrated a 73 percent reduction in average pain over 24 months.iiClinical outcomes from 100 patients presented at the International Society for the Advancement of Spine Surgery (ISASS) 2018 Annual Meeting showed the SImmetry System provided a 56 percent reduction in patient-reported pain, and a statistically significant reduction in the use of opioids and other pain medications at six months.iii

For more information on the policy, visit the HealthPartners website.

About RTI Surgical, Inc.

RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic and trauma procedures and are distributed in nearly 50 countries. RTI has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit Connect with us on LinkedIn and Twitter.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements, gaining market share and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at or the SEC’s website at

i Araghi A et al. Pain and Opioid use Outcomes Following Minimally Invasive Sacroiliac Joint Fusion with Decortication and Bone Grafting: The Evolusion Clinical Trial. Open Orthop J. 2017;11:1440-1448.
ii Cross W et al. Minimally Invasive Sacroiliac Joint Fusion: 2-Year Radiographic and Clinical Outcomes with a Principles-Based SIJ Fusion System. Open Orthop J. 2018 Jan 17;12:7-16.
iii Araghi A et al. Minimally invasive Sacroiliac Surgery with Decortication and Threaded Implants: Analysis of the EVoluSIon Study. Presented at ISASS 2018.


Media Contact

Molly Poarch, +1 224 287 2661

Investor Contact

Nathan Elwell, +1 847 530 0249

Value-Based Reimbursement Reduces Costs 15.6%, Improves Quality

November 14, 2018 / By Jacqueline LaPointe

Value-based reimbursement models are moving the needle on quality and cost, a new analysis from Humana shows.

In 2017, medical costs for patients attributed to primary care practices (PCPs) in Humana’s value-based reimbursement models for Medicare Advantage (MA) were 15.6 percent lower compared to Medicare fee-for-service, the insurer reported.

Internally, medical costs were also one percent lower for patients seeing PCPs in value-based payment models compared to patients treated by PCPs in Humana’s Medicare Advantage fee-for-service (FFS) setting.

“Humana MA value-based physicians had better results than their peers in FFS,” Kathryn Lueken, MD, MMM, Humana’s Corporate Medical Director of Medical Market Clinical Integration, wrote in the report. “The goal of taking costs out of the system and creating more value for the care received is showing results. Thus, value-based care is achieving the goal of creating higher quality medical care for lower cost.”

The transition to value-based care and payment has been a long and bumpy road for the healthcare industry.

READ MORE: Best Practices for Value-Based Purchasing Implementation

The Affordable Care Act really pushed the value-based care movement, but since then only about one-third of healthcare payments are tied to an alternative payment model with some degree of shared savings or risk, the Health Care Payment Learning & Action Network (LAN) recently reported.

Recent research also questions if value-based reimbursement can truly lower costs while maintaining or improving care quality. For example, a 2018 Healthcare Financial Management Association (HMFA) study of commercial payer and Medicare data from 2007 to 2015 found that the efficacy of alternative payment models reducing costs and improving care quality has yet to be proven.

However, value-based reimbursement at Humana is working to improve not only costs, but also utilization and quality, the insurer reported on Tuesday.

Patients in value-based reimbursement agreements were admitted to the hospital inpatient department 23.4 percent less than patients in traditional Medicare in 2017. And the patients went to the emergency room 15.6 percent less.

Even patients attributed to PCPs in bonus-only arrangements, which had limited upside shared savings, had fewer hospital admissions and emergency room visits. Hospital inpatient admissions and emergency room visits were 19.1 percent and 10.1 percent lower, respectively.




Smith & Nephew Presents Excellent Results for JOURNEY™ II Total Knee at the 2018 American Association of Hip and Knee Surgeons

MEMPHIS, Tenn., Nov. 16, 2018 /PRNewswire/ — Smith & Nephew (LSE: SN,NYSE: SNN), the global medical technology business, presented a number of compelling clinical outcomes around its flagship JOURNEY II BCS knee earlier this month at the American Association of Hip and Knee Surgeons (AAHKS). The announcement follows more than a dozen publications during the past year from various authors around the globe.1-14

In one of the largest multi-center retrospective patient cohorts ever studied, new clinical evidence represented excellent mid-term survivorship results on 2,059 patients with JOURNEY II BCS implants including:

  • About 1% of patients required major revision out to 6 years.15
  • No major or minor revision of any patient four years or more post-op.15
  • Five year revision rate that was reported as 3.6% compared to 4.1% for the cemented posterior stabilized (PS) class in the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR).15
  • Statistically significantly better survivorship for patients under 55 when compared to the Australian registry class average for the same age group at 6 years. The revision rate was 3% at 5 years for males and 3.1% for females, compared to 7% for males and 6.9% for females reported by the AOANJRR for cemented PS TKAs.15

These data add to the growing body of evidence that JOURNEY II TKA delivers smoother patient recovery, improved functional outcomes, higher patient satisfaction and healthcare cost-savings when compared with conventional TKAs.1,2,6,7,9,16,17

“It is very exciting to see additional clinical validation in such a large study showing excellent patient outcomes with our JOURNEY II TKA.  For years we at Smith & Nephew have been discussing the unique benefits of JOURNEY II knees and we are now seeing regular publications highlighting the improved outcomes compared to conventional TKAs.  These better-quality outcomes are a direct benefit to our surgeon customers and most importantly to their patients,” said Skip Kiil, President of Global Orthopaedics, Smith & Nephew.

JOURNEY II TKA first launched in late 2011 and now has more than 150,000 procedures performed worldwide.18

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic ReconstructionAdvanced Wound ManagementSports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN,NYSE: SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.comfollow @SmithNephewplc on Twitter or visit SmithNephewplc on

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.

 Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.


  1. Nodzo SR, Carroll KM, Mayman DJ. The Bicruciate Substituting Knee Design and Initial Experience. Tech Orthop.2018;33:37-41.
  2. Takubo A, Ryu K, Iriuchishima T, Tokuhashi Y. Comparison of muscle recovery following bicruciate substituting versus posterior stabilized total knee arthroplasty in an Asian population. J Knee Surg. 2017;30:725–729.
  3. Snyder M, Sympson A, Gregg J, Levit A. A comparison of patient reported outcomes between total knee arthroplasty patients receiving the Journey II bi-cruciate stabilizing knee system and total hip arthroplasty patients. Ortop Travmatol Protez. 2018;3:5-10.
  4. Christen B, Kopjar B. Second-generation bi-cruciate stabilized total knee system has a lower reoperation and revision rate than its predecessor. Arch Orthop Trauma Surg. 2018;138(11):1591-1599. https://doi: 10.1007/s00402-018-3019-5.
  5. Evangelista PJ, Laster SK, Lenz NM, Sheth NP, Schwarzkopf R. A Computer Model of Mid-Flexion Instability in a Balanced Total Knee Arthroplasty. J Arthroplasty. 2018;33(7S):S265-S269.
  6. Grieco TF, Sharma A, Dessinger GM, Cates HE, Komistek RD. In Vivo Kinematic Comparison of a Bicruciate Stabilized Total Knee Arthroplasty and the Normal Knee Using Fluoroscopy. The Journal of Arthroplasty. 2018;33(2):565-571.
  7. Kaneko T, Kono N, Mochizuki Y, Hada M, Toyoda S, Musha Y. Bi-cruciate substituting total knee arthroplasty improved medio-lateral instability in mid-flexion range. J Orthop. 2017;14(1):201-206.
  8. Harris AI, Luo TD, Lang JE, Kopjar B. Short-term safety and effectiveness of a second-generation motion-guided total knee system. Arthroplasty today. 2018;4(2):240-243.
  9. Iriuchishima T, Ryu K. A Comparison of Rollback Ratio between Bicruciate Substituting Total Knee Arthroplasty and Oxford Unicompartmental Knee Arthroplasty. J Knee Surgery. 2018;31(6):568-572.
  10. Murakami K, Hamai S, Okazaki K, et al. Knee kinematics in bi-cruciate stabilized total knee arthroplasty during squatting and stair-climbing activities. J Orthop. 2018a;15(2):650-654.
  11. Murakami K, Hamai S, Okazaki K, et al. Preoperative tibial mechanical axis orientation and articular surface design influence on the coronal joint line orientation relative to the ground during gait after total knee arthroplasties. Knee Surg Sports Traumatol Arthrosc2018b;26:3368-3376.
  12. Murakami K, Hamai S, Okazaki K, et al. In vivo kinematics of gait in posterior-stabilized and bicruciate-stabilized total knee arthroplasties using image-matching techniques. Int Orthop. 2018c;42:2573-2581.
  13. Zambianchi F, Fiacchi F, Lombari V, et al. Changes in total knee arthroplasty design affect in-vivo kinematics in a redesigned total knee system: A fluoroscopy study. Clin Biomech (Bristol, Avon). 2018;54:92-102.
  14. Lutes W and Fitch D. Comparison of functional outcomes following total knee arthroplasty with a conventional implant design or one designed to mimic natural knee kinematics. Presented at: 39th SICOT Orthopaedic World Congress; October 10-13, 2018; Montréal, Canada.
  15. Harris AI. Performance of second-generation guided motion total knee arthroplasty system: Results from the international multicenter study of over 2,000 primary TKA with up to 6 Years follow-up. Poster presented at AAHKS Annual Meeting. November 1-4 2018Dallas, Texas, USA.
  16. Mayman DJ, Patel AR, Carroll KM. Hospital Related Clinical and Economic Outcomes of a Bicruciate Knee System in Total Knee Arthroplasty Patients. Poster presented at: ISPOR Symposium; May 19-23, 2018Baltimore, Maryland, USA.
  17. Kosse NM, Heesterbeek PJC, Defoort KC, Wymenga AB, van Hellemondt GG. Minor adaptations in implant design bicruciate-substituted total knee system improve maximal flexion. Poster presented at: 2nd World Arthroplasty Congress; 19-21 April, 2018Rome, Italy.
  18. Data on file with Smith & Nephew.

SOURCE Smith & Nephew

Related Links

AlloSource Granted Patent For Proprietary Laser Cutting Enclosure

CENTENNIAL, Colo.Nov. 16, 2018 /PRNewswire/ — AlloSource, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, received U.S. patent 10,105,793, titled Enclosure for laser cutting of human tissue.

This patent encompasses AlloSource’s method of producing a closed system that allows a laser beam to pass through and etch allograft tissue, while maintaining a sterile barrier. The proprietary method expedites processing, maximizes the use of tissue, and allows utilization of a specialized laser technology in a clean room setting.

The process is used to create ProChondrix® CR, AlloSource’s fresh cryopreserved osteochondral allograft. ProChondrix CR helps deliver the necessary components for articular cartilage restoration. This next generation of cartilage restoration therapy provides living functional cells and other biological components necessary for replacement, repair and regeneration of damaged cartilage tissues.

“As an organization dedicated to honoring tissue donation, this patent is a great example of our commitment to innovation,” said Dr. Ross Wilkins, AlloSource Senior Medical Director. “Laser etching stimulates the cartilage regenerative system while the graft replaces the missing cartilage in superficial defects down to the bone level. The early clinical results are very encouraging.”

About AlloSource 
AlloSource is dedicated to advancing the science and use of transplantable allogeneic cells and tissue through pioneering research in regenerative therapies. The organization offers life-saving and life-enhancing solutions in orthopedic, spine, burn and wound procedures to help restore patient health and mobility. As a world leader in cell-based products, fresh cartilage tissue for joint repair and skin allografts to help heal severe burns, AlloSource’s products bridge the proven science of allografts with the advanced technology of cells. The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, CO. For more information, please visit

Media Contact 
Megan Duggan
720. 382. 2766

SOURCE AlloSource

Related Links

Premier Inc. Survey: Nearly 75% of Health Systems Report Interest in Value-Based Contracting

November 15, 2018

CHARLOTTE, N.C. – Although 73 percent of healthcare providers rank value-based contracting with suppliers as a priority for improving return on investments, opportunities lag in the healthcare supply chain, according to a new Premier Inc. survey .

Premier®, a leading healthcare improvement company, surveyed health system C-suite leaders, operations managers and heads of materials management to determine the prevalence of value-based contracts for products and services across the industry, as well as potential barriers to implementation. Broadly, value-based contracts are those with terms and conditions that hold suppliers accountable for delivering on cost, service or product attribute guarantees.

According to the survey, 38 percent of respondents participate in added value programs, requiring suppliers to meet or beat historical pricing targets or guarantee specific service levels. However, only 16 percent of respondents participate in true, value-based, two-sided risk contracts with suppliers, where the vendor agrees to pay providers back for costs incurred if their product fails to meet pre-determined cost and quality outcomes.

“In today’s healthcare environment, health systems are increasingly being pushed to assume risk for the total cost and quality outcomes of all delivered care,” said Myla Maloney, Vice President of Strategic Accounts for Premier Applied Sciences. “In an environment where value is the new economy and measures are its currency, we are seeing an uptick in the number of providers interested in securing outcome guarantees from their business partners. The challenge is that value-based contracts between providers and suppliers are a relatively new phenomenon, and there are few best practice examples for how they should be structured.”

A majority of providers indicated a lack of understanding of value-based, two-sided risk contracts in the supply chain (55 percent of respondents) as the main reason they have not implemented one.

Of the value-based contracts that have been deployed, respondents indicated that the most common are for surgical services, with 13 percent of respondents reporting contracts in this category, followed by cardiovascular (12 percent) and purchased services (11 percent) categories. However, respondents faced challenges to implementation, mainly around access to and agreement on the data sources that would be used to evaluate performance (22 percent), as well as internal communications about the structure of the contracts and how they should be implemented (14 percent).

Additionally, although 81 percent of respondents said they were interested in securing more of these types of contracts, most indicated they were unable to do so due to a lack of supplier engagement, cited by 67 percent of all respondents.

Premier actively works with its members to develop and deploy value-based contracts across a range of suppliers and product lines. Leveraging the PremierConnect® performance improvement platform with clinical outcomes data on 45 percent of all U.S. inpatient discharges, Premier has the ability to mine data and develop relevant outcomes metrics that can be tracked and validated by scientific best practices. Moreover, as a leading contracting entity in healthcare, Premier can secure supplier interest and deploy value-based contracts at scale by making them available across its membership base.

Premier has negotiated a range of value-based contracts with suppliers, including:

  • Evidence-based care discounts: More common among pharmaceutical companies, these contracts provide a discount off the purchase price in exchange for the reliable performance of an evidence-based clinical intervention. For instance, a perioperative nutritional supplement maker under contract with Premier gives a price discount if health systems can document that they are discussing perioperative nutrition as part of their standard care model.
  • Product or service guarantee: These contracts reimburse health systems for the purchase price of a product in the event of a quality or performance failure. One interventional device company under contract with Premier guarantees that the use of its product will reduce pressure ulcer rates by a specific percentage. If that commitment is not met, the providers are eligible for a rebate.
  • Risk share by product: These contracts reimburse providers for another, added cost in the system as a result of a poor outcome, as opposed to the actual cost of the product. For instance, one cardiovascular device company under contract with Premier reimburses health systems for the cost of treating a specific type of infection if a patient contracts it within six months of receiving their intervention.

Survey Methodology

Premier’s survey on value-based contracting trends was conducted online, with the results based off responses from 203 healthcare leaders, including the C-suite (CEO, COO, CMO, CFO, CIO or CTIO), as well as heads of materials management and operations from October 2 – October 22, 2018. Survey respondents included both members and non-members of Premier.

About Premier, Inc.

Premier Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of approximately 4,000 U.S. hospitals and health systems and approximately 165,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost. Premier plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on; as well as TwitterFacebookLinkedInYouTubeInstagram, and Premier’s blog for more information about the company.